Download Free Cognitive Enhancement In Schizophrenia And Related Disorders Book in PDF and EPUB Free Download. You can read online Cognitive Enhancement In Schizophrenia And Related Disorders and write the review.

A practical guide on how to assess and treat schizophrenia and related disorders using cognitive rehabilitation.
Schizophrenia and related psychiatric disorders can be highly disabling. Deficits in cognition, involving skills such as attention, problem solving and social understanding are core symptoms of many psychiatric disorders, which greatly impact the quality of life of patients. New research demonstrates the evidence for cognitive enhancement therapies, capable of relieving these deficits. This book explores the evidence for cognitive enhancement therapies and their mode of action, making recommendations for individualized implementation strategies. The topics covered include computer-based exercises, psychotherapeutic group activities, and pharmacological interventions. This book is designed to serve the needs of practicing clinicians, researchers, and mental health students. It is packed full of illustrations and case vignettes from the author's own practice and includes an up-to-date bibliography of the major works in this field.
Social Cognition in Schizophrenia: From Evidence to Treatment provides a firm grounding in the theory and research of normal social cognition, builds on this base to describe how social cognition appears to be dysfunctional in schizophrenia, and explains how this dysfunction might be ameliorated.
Disturbances of various domains of cognitive function have been shown to provide a major determinant of outcome for patients with psychiatric conditions. Cognitive impairment is present in an array of diseases, including schizophrenia (with its prodromal stage), mood disorder, autism spectrum disorder, obsessive-compulsive disorder, anxiety disorder, post-traumatic disorder, and eating disorder. In an effort to develop effective therapeutics for cognitive impairment, bridging of preclinical and clinical evidence has been attempted. This edited Book will provide a forum for researchers and clinicians interested in the phenomenology, underlying mechanisms, and treatment of cognitive impairment associated with psychiatric illnesses. Twenty-eight contributions from 8 countries in Europe, Middle East, Asia, North America, and South America represent studies dealing with genetic, molecular, imaging, physiological, psychological, and behavioral issues. Information in this Book will facilitate the development of therapeutics of greater clinical value.
This book highlights recent research investigating psychological and neural mechanisms contributing to dysfunctional cognition in people with schizophrenia. The work on cognition in schizophrenia from the past 20 years is highlighted, and emphasis throughout the book is placed on utilizing the Research Domain Criterion framework. Thus, the book also covers animals work relevant to schizophrenia that assesses behaviors utilizing the same framework, enabling mechanistic studies and highlighting potential biomarkers of function. The book also includes important areas of research in the field of cognitive function in schizophrenia that have received less attention, such as cognitive side-effects of current treatments and olfactory-based cognition. Altogether, the book provides a translational perspective of the most-up-to-date research on cognition in schizophrenia to-date, but with identification of novel directions for research initiatives..
Research shows that neuro- and social cognition have a decisive influence on functional outcome in people with schizophrenia. In this publication, world-renowned experts summarize the latest research on approaches to assessing and treating cognition in schizophrenia. The book is organized to take the reader through the steps from definitions and assessment of cognition to research on the relevance of cognition in everyday life, to chapters which focus on treatments for cognitive disorders. The reader will learn about the NIMH MATRICS initiative which has provided clinicians and researchers with the tools to define and assess neuro- and social cognitive functioning in people with schizophrenia. Then the treatments for neuro and social cognitive deficits are discussed in several chapters which give an overview of cognitive remediation approaches, accompanied by concrete treatment examples. The reader will also learn about the latest results of pharmacological interventions for cognitive deficits. A final chapter focuses on the importance of addressing motivational deficits when treating cognition, and offers treatment approaches to enhance motivation. This publication is essential reading for clinicians and researchers in the fields of psychiatry, psychology as well as students and other professions working with people who have schizophrenia.
For the first time in a single volume, distinguished experts address the complex issues -- issues rarely confronted in empirical studies of patients with schizophrenia -- and controversial research surrounding the assessment of negative symptoms and cognitive deficits in patients with schizophrenia. Despite recent advances in our understanding of schizophrenia, still notably absent is consensus in assessing negative symptom treatment response. What is the most effective assessment method -- given the varying methodologies and contradictory results to date? What constitutes an adequate response? Which medication -- none is specifically indicated and licensed for negative symptom treatment -- yields the best results? What are the indications for use of this medication? Which instrument best measures negative symptom treatment response (eight rating scales are analyzed here)? Reaching consensus among clinicians and researchers alike is even more difficult because assessment is often thwarted by extrapyramidal side effects of medications, similarities to depressive symptoms, and secondary effects of psychotic experiences. In addition to clarifying these pressing issues, Negative Symptom and Cognitive Deficit Treatment Response in Schizophrenia also discusses The importance of measuring the experience of emotion versus the more traditional objectively measured symptoms in patients with schizophrenia, and how deficits in emotional experience may resist treatment -- even in treatment-responsive patients. The family as an often overlooked source of information about negative symptom improvement or worsening, and the impact of negative symptoms on patients' relatives. How treatment affects social functioning and subjective experience of "quality of life," and the importance of neurocognitive dysfunction in the social deficits of schizophrenia, which often persist despite significant amelioration of other symptoms. Specific guidelines for assessing neurocognitive treatment response. Cognitive enhancement is a major factor in improving the quality of patients' lives. The latest research on the neurobiology of negative symptoms, including the role of various neurotransmitter systems and brain regions in mediating negative symptom pathology. Also discussed is single vs. multiple pathophysiological processes and single treatment modality vs. distinct treatments for different aspects of negative symptoms. How to distinguish "pure" negative symptoms from deficit symptoms (i.e., those that persist for at least 1 year and are not secondary to factors such as depression, medication side effects, anxiety, delusions, and hallucinations), and which treatment is indicated for each. Highlighted by patient vignettes, this in-depth guide will be welcomed by all clinicians who treat patients with schizophrenia and want to know and document whether their interventions ameliorate negative symptoms and cognitive dysfunction, and by all researchers who study schizophrenia, particularly those interested in clinical issues and treatment studies.
Provides state-of-the-art information about cognition in schizophrenia with a wide ranging focus on measuring and treating cognitive deficits.
Cognitive Enhancement in CNS Disorders and Beyond compiles a series of educational and thought-provoking chapters from the world's leading cognitive and clinical scientists to describe the latest research on cognitive impairments in a host of pathological conditions that affect CNS functioning, what treatments are available for these impairments, and how new treatments are being tested. This volume will benefit any investigators in cognitive science and clinical research, but is also accessible to non-experts. It advances the field toward the availability of cognitive enhancing drugs and devices that will benefit those who need them most and others who may feel that these techniques can help them to thrive. There has never been a time that we knew more about cognition and never a time when cognition was more important to the functioning of human beings than right now. Psychological science and cognitive neuroscience have become the most popular endeavor of students world wide, is the focus of attention of our greatest scientific accomplishments and the emphasis of many publications in the mainstream media. Since humans depend on cognitive abilities for survival, quality of life, and productivity, improving it has never been more important. Those with impairments in key aspects of cognition suffer dearly, as they are unable to obtain and retain information, unable to make sound decisions based upon the information at hand, and unable to plan future activities. The availability of pharmacological and behavioral interventions that can improve cognitive abilities and provide impaired individuals with the social, occupational and functional quality of life that the rest of us enjoy has potential far-reaching implications. Such interventions can also benefit those who want to boost current cognitive abilities to higher levels, perhaps as a means to hone skills in providing products for others or to gain an edge on competition. There has never been a book devoted solely to describing the latest cognitive science and neuroscience on the methods for enhancing cognition in healthy and unhealthy humans. Cognitive Enhancement in CNS Disorders and Beyond accomplishes exactly that in a straightforward and accessible manner.
Although it has been known for 100 years that cognitive functioning is impaired in schizophrenia, the implications of this impairment have only recently been clearly understood. While in the past, cognitive deficits were thought to be the result of other aspects of the illness, such as poor co-operation, or as a result of the treatment of the illness, it is now known that these factors exert only a very minor influence on cognitive deficit. This book, with contributions from the major international names in the field, reviews the most recent research on the impairment of cognitive functioning in schizophrenia, covering: what it is, how wide-ranging it can be, what the clinical implications are, and how it can be treated? A detailed insight into cognitive deficit is the key to understanding why previous treatments have failed, and the key by which new treatments may change this terrible illness, treatments significantly more effective than earlier interventions.